Medytox Posts KRW 7.4 Billion Operating Profit in Q1, Up 35% Year-on-Year

On May 12, Medytox announced its consolidated results for the first quarter of this year, reporting sales of KRW 60.7 billion, operating profit of KRW 7.4 billion, and net profit of KRW 7.9 billion. While sales decreased by 5% compared to the same period last year, operating profit and net profit increased by 35% and 136%, respectively.

This performance is attributed to the company’s strategy of strengthening core business competitiveness and improving profitability, particularly focused on its main business of botulinum toxin formulations. According to the company, sustained growth of “Medytoxins” and “Newlux” in overseas markets, as well as increased domestic sales of the premium toxin formulation “Coretox,” had a positive impact on profitability.

Medytox continues to expand its presence in both domestic and international markets with a differentiated botulinum toxin portfolio consisting of four products: “Medytoxins,” “Innotox,” “Coretox,” and “Newlux.” In particular, the company is accelerating efforts to enter the global market and expand approvals for “Newlux,” its next-generation toxin formulation, developed by its subsidiary. Medytox is also focusing on strengthening distribution networks in major countries and ramping up local marketing activities.

Additionally, the submental fat reduction injection “Newviju,” which was launched at the end of March, has already contributed to the first quarter results through some pre-orders, and is drawing attention as a new growth driver. Medytox plans to further strengthen its aesthetics portfolio and enhance market competitiveness through “Newviju.” At the same time, the company is moving forward as planned with its global expansion strategy for key products, including the next-generation liquid-type botulinum toxin formulation “MT10109L.” Medytox intends to focus on reinforcing its mid- to long-term growth foundation, leveraging its research and development capabilities.

A Medytox representative stated, “We are continuously pursuing management strategies to improve profitability based on the competitiveness of our core botulinum toxin business,” adding, “We will continue to strengthen our growth foundation by expanding the global market for next-generation products and ensuring the smooth execution of major projects.”

This content was produced with the assistance of AI translation services.